No abstract

Abstract-A photonic packet switching node is introduced, and its routing latency is shown to be 15.3 ns. The power penalty of the node at a bit-error rate (BER) of 10 9 is confirmed to be approximately 0.2 dB across 33 nm of the -band for 10-Gb/s payload wavelengths. Moreover, multiple-wavelength packets containing 16 payload wavelengths can be switched while maintaining BERs of 10 12 or better.Index Terms-Interconnection networks, packet switching, photonic switching systems, wavelength-division multiplexing (WDM).

No abstract

Copper (Cu) plays a pivotal role in cancer progression by acting as a co-factor that regulates the activity of many enzymes and structural proteins in cancer cells. Therefore, Cu-based complexes have been investigated as novel anticancer metallodrugs and are considered as a complementary strategy for currently used platinum agents with undesirable general toxicity. Due to the high failure rate and increased cost of new drugs, there is a global drive towards the repositioning of known drugs for cancer treatment in recent years. Disulfiram (DSF) is a first-line antialcoholism drug used in clinics for more than 65 yr. In combination with Cu, it has shown great potential as an anticancer drug by targeting a wide range of cancers. The reaction between DSF and Cu ions forms a copper diethyldithiocarbamate complex (Cu(DDC)2 also known as CuET) which is the active, potent anticancer ingredient through inhibition of NF-κB and ubiquitin-proteasome system as well as alteration of the intracellular reactive oxygen species (ROS). Importantly, DSF/Cu inhibits several molecular targets related to drug resistance, stemness, angiogenesis and metastasis and is thus considered as a novel strategy for overcoming tumour recurrence and relapse in patients. Despite its excellent anticancer efficacy, DSF has proven unsuccessful in several cancer clinical trials. This is likely due to the poor stability, rapid metabolism and/or short plasma half-life of the currently used oral version of DSF and the inability to form Cu(DDC)2 at relevant concentrations in tumour tissues. Here, we summarize the scientific rationale, molecular targets, and mechanisms of action of DSF/Cu in cancer cells and the outcomes of oral DSF ± Cu in cancer clinical trials. We will focus on the novel insights on harnessing the immune system and hypoxic microenvironment using DSF/Cu complex and discuss the emerging delivery strategies that can overcome the shortcomings of DSF-based anticancer therapies and provide opportunities for translation of DSF/Cu or its Cu(DDC)2 complex into cancer therapeutics.

Abstract-A complete review of the data vortex optical packet switched (OPS) interconnection network architecture is presented. The distributed multistage network topology is based on a banyan structure and incorporates a deflection routing scheme ideally suited for implementation with optical components. An implemented 12-port system prototype employs broadband semiconductor optical amplifier switching nodes and is capable of successfully routing multichannel wavelength-division multiplexing packets while maintaining practically error-free signal integrity (BER 10 12 ) with median latencies of 110 ns. Packet contentions are resolved without the use of optical buffers via a distributed deflection routing control scheme. The entire payload path in the optical domain exhibits a capacity of nearly 1 Tb/s. Further experimental measurements investigate the OPS interconnection network's flexibility and robustness in terms of optical power dynamic range and network timing. Subsequent experimental investigations support the physical layer scalability of the implemented architecture and serve to substantiate the merits of the data vortex OPS network architectural paradigm. Finally, modified design considerations that aim to increase the network throughput and device-level performance are presented.Index Terms-Interconnection networks (multiprocessor), optical interconnections, packet switching, photonic switching systems, wavelength-division multiplexing.